SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT01408719

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Effect of Beta-Glucan Molecular Weight and Viscosity on the Mechanism of Cholesterol Lowering in Humans

The primary aim of this study is to determine whether the cholesterol-lowering efficacy of barley b- glucan varied as function of molecular weight (MW) and the total daily amount consumed. Our second aim is to investigate the mechanism responsible for the action, specifically, whether β-glucan lowers circulating cholesterol concentration via inhibiting cholesterol absorption and synthesis. Thirdly, we aim to determine if any gene-diet interactions are associated with cholesterol lowering by barley β-glucan. In addition, we aim to investigate the alteration of the gut microbiota after β-glucan consumption and the correlation between the altered gut microbiota and cardiovascular disease risk factors.

NCT01408719 Hypercholesterolemia
MeSH: Hypercholesterolemia
HPO: Hypercholesterolemia

4 Interventions

Name: Control

Description: Minimal beta-glucan

Type: Dietary Supplement

5g LMW beta glucan

Name: 3g LMW beta-glucan

Description: 3grams beta-glucan

Type: Dietary Supplement

3g HMW beta glucan

Name: 5g LMW beta-glucan

Description: 5 grams beta-glucan

Type: Dietary Supplement

3g LMW beta glucan

Name: 3g HMW beta-glucan

Description: 3 grams of high molecular weight beta-glucan

Type: Dietary Supplement

Control


Primary Outcomes

Description: Fasted total cholesterol concentration will be measured using the automated enzymatic methods.

Measure: Changs in Total Cholesterol

Time: Beginning and end of each phase

Description: Serum LDL cholesterol will be estimated using the Friedewald equation.

Measure: Changes in LDL Cholesterol

Time: Beginning and end of each phase

Secondary Outcomes

Description: The rate of cholesterol absorption and synthesis will be measured in each intervention phase using single stable isotope labelling technique.

Measure: Cholesterol Absorption/Synthesis

Time: End of each phase

Description: The Single Nucleotide Polymorphism (SNP) rs3808607 of CYP7A1 gene, rs429358 and rs7412 of APOE gene, and their associations with different blood lipid responses to beta-glucan interventions will be determined.

Measure: Potential Gene-nutrient Interactions: CYP7A1 and APOE

Time: Once for each participant

Description: Body weight will be monitored every day when subject visits the Richardson Centre. Waist circumference will be measured at the beginning and end of each study phase.

Measure: Changes in Body Weight and Waist Circumference(WC)

Time: Every day for body weight; beginning and end of each phase for WC

Purpose: Prevention

Allocation: Randomized

Crossover Assignment


There are 3 SNPs

SNPs


1 rs3808607

The Single Nucleotide Polymorphism (SNP) rs3808607 of CYP7A1 gene, rs429358 and rs7412 of APOE gene, and their associations with different blood lipid responses to beta-glucan interventions will be determined.. Changes in Body Weight and Waist Circumference(WC).

Single nucleotide polymorphisms (SNPs), rs3808607 of gene CYP7A1and rs429358 and rs7412 will be determined byTaqMan® SNP Genotyping assay following the manufacturer's protocol.


2 rs429358

The Single Nucleotide Polymorphism (SNP) rs3808607 of CYP7A1 gene, rs429358 and rs7412 of APOE gene, and their associations with different blood lipid responses to beta-glucan interventions will be determined.. Changes in Body Weight and Waist Circumference(WC).

Single nucleotide polymorphisms (SNPs), rs3808607 of gene CYP7A1and rs429358 and rs7412 will be determined byTaqMan® SNP Genotyping assay following the manufacturer's protocol.


3 rs7412

The Single Nucleotide Polymorphism (SNP) rs3808607 of CYP7A1 gene, rs429358 and rs7412 of APOE gene, and their associations with different blood lipid responses to beta-glucan interventions will be determined.. Changes in Body Weight and Waist Circumference(WC).

Single nucleotide polymorphisms (SNPs), rs3808607 of gene CYP7A1and rs429358 and rs7412 will be determined byTaqMan® SNP Genotyping assay following the manufacturer's protocol.



HPO Nodes


HPO:
Hypercholesterolemia
Genes 39
GHR LDLRAP1 PHKA2 FLII PYGL APOB LIPA OCRL SETX APOC3 CAV1 DEAF1 CAV3 APOE CCDC115 TDP1 SLC7A7 LMNA NUP107 RSPO1 TTPA CYP7A1 LDLR PIK3R5 CETP COG4 ABCG5 ABCG8 SLC25A13 JAG1 DGAT1 RAI1 APTX IQSEC2 CYP27A1 PCSK9 CEP19 DYRK1B TMEM199